ORIC Oric Pharmaceuticals8.27+0.80 (+10.6%)
After Hours Decliner
ORIC Oric Pharmaceuticals12.67+0.48+3.9%
After Hours:9.48-3.19 (-25.2%)
ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Globe NewswireTue, 31-Mar 4:05 PM
ORIC Oric Pharmaceuticals11.04-0.10 (-0.9%)
ORIC Oric Pharmaceuticals9.39+0.17 (+1.8%)
ORIC Oric Pharmaceuticals8.00+2.03 (+34.0%)